Clinical Trial Update: Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anti-PD-1/PD-L1 antibodies in combination with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-PD-1/PD-L1 antibodies
• Bevacizumab (bevacizumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: EuroCityClinic LLC | Conditions: Metastatic Non-small Cell Lung Cancer (NSCLC), Metastatic Cutaneous Melanoma | Phase 2 | Status: RECRUITING